<DOC>
	<DOCNO>NCT00752310</DOCNO>
	<brief_summary>The purpose study evaluate healthy volunteer much fast new suspension compare commercial darunavir tablet , give combination low-dose ritonavir , absorb body ( call relative oral bioavailability ) .</brief_summary>
	<brief_title>TMC114-TiDP29-C169 : Bioavailability Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation Current Darunavir Tablet</brief_title>
	<detailed_description>The objective trial Part 1 compare rate extent absorption single oral dose 600 mg darunavir ( DRV ) administer suspension formulation F051 ( feed fast condition ) commercial tablet formulation F016 ( fed condition ) , presence low-dose ritonavir healthy volunteer ; compare rate extent absorption single oral dose 600 mg DRV administer suspension formulation F051 feed condition fast condition , presence low-dose ritonavir healthy volunteer . In Part 2 want ass multiple dose pharmacokinetics DRV administer suspension formulation F051 ( feed fast condition , base result Part 1 ) , presence low-dose ritonavir healthy volunteer . The short-term safety tolerability DRV evaluate follow administration 3 single oral dos 600 mg ( formulate suspension tablet ) follow administration multiple oral dos ( formulate suspension ) , presence low-dose ritonavir healthy volunteer Part 1 : 3 session volunteer orally receive 3 single dos 600 mg darunavir ( DRV ) : 2 tablet 300 mg 6 ml suspension feed condition 6 mL suspension ( 100 mg/mL ) fast condition Day 3 . Part 2 : subject receive DRV suspension , twice daily Day 1 6 , additional morning dose Day 7 . In Part I rtv 100 mg coadministered twice daily Day 1 Day 5 Part 2 Day 1 Day 9 .</detailed_description>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Nonsmoking , smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior selection Normal weight define Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Able comply protocol requirement . Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , electrocardiogram ( ECG ) , vital sign , result blood biochemistry , blood coagulation , hematology test urinalysis carry screen . No positive HIV 1 HIV 2 test screen history significant skin disease , limited rash eruption , drug allergy , food allergy , dermatitis , eczema , psoriasis , urticaria history allergy drug , limit , sulphonamides penicillins previously demonstrate clinically significant allergy hypersensitivity excipients investigational medication administer trial female subject childbearing potential without use effective nonhormonal birth control method , willing continue practice birth control method least 30 day end treatment period positive pregnancy test breast feeding screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC114-TiDP29-C169</keyword>
	<keyword>TMC114-C169</keyword>
	<keyword>Darunavir ( suspension formulation )</keyword>
</DOC>